Differential effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19

lianjiu su

Wuhan University Zhongnan Hospital

jiahao zhang

Wuhan University Zhongnan Hospital

nanhui jiang

Wuhan University Zhongnan Hospital

jie yang

Huazhong University of Science and Technology

li he

Wuhan University Zhongnan Hospital

qin xie

Wuhan University Zhongnan Hospital

rong huang

Wuhan University Zhongnan Hospital

fang liu

Wuhan University Zhongnan Hospital

ying feng

Wuhan University Zhongnan Hospital

Kianoush B. Kashani

Mayo Clinic Minnesota

qiaofa lu

Huazhong University of Science and Technology School of Foreign Languages

zhongyi sun (✉ zhongyisun920926@163.com)

Guangxi Medical University <https://orcid.org/0000-0002-1285-2177>

zhiyong peng

Wuhan University Zhongnan Hospital

Research article

Keywords: COVID-19, angiotensin-converting enzyme inhibitors, hypertension, ARDS

Posted Date: August 31st, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-57987/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

The effect of angiotensin-converting enzyme inhibitor/angiotensin receptor blockers (ACEI/ARB) on the COVID-19 remains controversial from clinic evidence.

Methods

This is a retrospective, two-center case series of 198 consecutive COVID-19 patients with a history of hypertension.

Results

Among 198 patients, 58 (29.3%) and 16 (8.1%) were on were on ARB and ACEI, respectively. Patients who were on ARB or ACEI/ARB had a significantly lower rate of severe illness and ARDS when compared with patients treated with ACEI alone or not receiving and RAAS blocker ($P=0.05$). The Kaplan-Meier survival curve showed that patients with ARB in their antihypertensive regimen had a trend towards a higher survival rate when compared with individuals without ARB (adjusted hazard ratio, 0.27; 95% CI, 0.07-1.02; $P = 0.054$). The Cox-regression analysis to compared ACEI vs. ARB groups showed a significantly lower mortality rate in the ARB group (adjusted hazard ratio, 0.03; 95% CI, 0.00-0.58; $P = 0.02$).

Conclusions

Using of ARB was associated with a reduced rate of severe illness and ARDS, indicating their potential protective impact in COVID-19.

Introduction

The novel coronavirus SARS-CoV-2, which has caused a pandemic of coronavirus disease 2019 (COVID-19), has become a serious threat to human health globally. This disease particularly poses a tremendous hazard to individuals with coexisting comorbidities, including old age and chronic diseases such as hypertension, diabetes mellitus, and chronic lung diseases^{1,2}. Similar to SARS-CoV, SARS-CoV-2 utilizes angiotensin-converting enzyme-2 (ACE2) protein on the cell membrane as its host receptor³. Angiotensin-Converting Enzyme Inhibitors (ACEI) and Angiotensin II Receptor Blockers (ARB) are commonly used in hypertensive in COVID-19 patients with hypertension. Thus, there is an increasing interest in the potential effects of these drugs on the outcomes of patients with COVID-19⁴. Recently, in a Chinese retrospective study, Zhang et al. reported ACEI/ARB to exhibit a remarkable association with reduced mortality of COVID-19 patients with hypertension⁵. A similar study by Li et al. showed ACEI/ARB not affecting the outcome of COVID-19 patients. However, there may be some differences between the use of ACEI vs. ARB on the outcomes. On the other hand, a previous study showed that the ACEI and ARB differed in the expression of ACE2 in an animal experiment⁶, suggesting the possibility of differential effects on COVID-

19 patients. Of note, it has been reported that East Asian patients have higher incidence of ACEI-induced cough⁷. Therefore, ARB is the predominant drug used in China to block the renin-angiotensin-aldosterone system (RAAS). As the effect of ACEI/ARB on the outcomes of COVID-19 patients is still controversial, we aimed to assess the characteristics and clinical outcomes of patients with a history of hypertension treated with ACEI vs. ARB who developed COVID-19.

Methods

Study Design and Participants

In this retrospective cohort study, we included 198 consecutive COVID-19 patients with a history of hypertension who were admitted between December 26, 2019, and March 6, 2020, at Zhongnan Hospital of Wuhan University and Wuhan Fourth Hospital in Wuhan city, China. We did not exclude patients who needed to discontinue antihypertensive medications due to hypotension, not being able to take oral medicines, or had an increase in their serum creatinine level. The diagnosis of COVID-19 was according to the World Health Organization (WHO) interim guidance⁸. RT-PCR assay was performed to confirm the COVID-19 diagnosis when necessary, based on the WHO established protocol. The local institutional review boards approved this study, and informed consent was obtained from patients or their legal representatives.

Data collection

Demographics, laboratory values, treatment strategies, complications, and clinical outcomes of patients were abstracted from the medical records using a standardized report form designed for this study. The clinical symptoms and laboratory findings at hospital admission and complications and clinical outcomes throughout the hospitalization were collected. Acute respiratory distress syndrome (ARDS) was defined according to the Berlin definition⁹. The severe condition of COVID-19 was determined using the guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)¹⁰. Acute kidney injury was defined based on the KDIGO (Kidney Disease: Improving Global Outcomes) criteria¹¹. Acute liver injury was defined according to the EASL Clinical Practice Guidelines¹². The primary outcome of this study was survival. The secondary outcomes included the severity of illness, ARDS, acute liver injury, and acute kidney injury. Patients' follow-up times were defined as the time interval from hospitalization to the most recent contact or the time of patient death, whichever came earlier. The latest follow-up date was March 15, 2020.

Statistical analysis

The continuous variables were summarized as medians and interquartile ranges and compared by the Mann-Whitney-Wilcoxon test. The categorical data were summarized using frequencies and percentages and examined by the chi-square test or the Fisher exact test, as appropriate. The logistic regression model was used to assess the odds ratio of treatment with ACEI vs. ARB on the severity of illness and ARDS. The survival curves of COVID-19 patients were assessed by Kaplan-Meier plots using the log-rank test.

The Cox proportional hazards regression model was used to determine the hazard ratios of ACEI vs. ARB use on death. All tests were 2-sided, and P-value > 0.05 was considered as statistically significant. All analyses were conducted by Stata/SE version 12 (Stata Crop) and GraphPad Prism version 8 (GraphPad Software Inc).

Results

Participants

A total of 198 COVID-19 patients with hypertension were enrolled. Among these patients, 103 (52%) were women. The median (interquartile range [IQR]) age of patients was 65 (56, 73) years, with a length of hospital stay of 14 (9, 21) days, and an overall follow-up of 38 (29, 53) days. There were 74 (37.4%) patients who were on ACEI [16(8%)] or ARB [58(29.3%)] treatment. Of these patients, 87 (43.9%) were severely ill, 69 (34.8%) patients developed ARDS, and 22 (11.1%) died. The characteristics of patients are summarized in Table 1.

Table 1
Patient characteristics based on history of treatment with ACEI/ARB

Characteristic	Total(N = 198)	ACEI/ARB(N = 74)	Non-ACEI/ARB(N = 124)	P
Age, median (IQR) - yr	65 (56–73)	66 (56–73)	65 (57–72)	0.755
Female sex - no. (%)	103 (52.0)	28 (37.8)	75 (60.5)	0.002
Comorbidities - no. (%)				
Diabetes	54 (27.3)	23 (31.1)	31 (25.0)	0.353
Cardiovascular disease	49 (24.7)	22 (29.7)	27 (21.8)	0.209
Cerebrovascular disease	20 (10.1)	9 (12.2)	11 (8.9)	0.457
Malignancy	17 (8.6)	7 (9.5)	10 (8.1)	0.735
Chronic kidney disease	11 (5.6)	2 (2.7)	9 (7.3)	0.215
Chronic obstructive pulmonary diseases	5 (2.5)	1 (1.4)	4 (3.2)	0.652
Chronic liver disease	2 (1.0)	1 (1.4)	1 (0.8)	1.000
Fever - no. (%)	173 (87.4)	62 (83.8)	111 (89.5)	0.240
Respiratory rate, median (IQR)	20 (19–22)	20 (19–22)	20 (19–22)	0.513
Pulse, median (IQR)	85 (78–96)	84 (78–91)	87 (79–100)	0.121
Systolic blood pressure	133 (123–145)	134 (130–146)	130 (120–145)	0.091
Diastolic blood pressure	80 (74–87)	80 (74–86)	80 (74–88)	0.412
Laboratory data, median (IQR)				
White blood cell count × 10 ⁹ /L	5.6 (4.2–7.3)	5.2 (4.2–6.8)	5.8 (4.2–7.7)	0.323
Lymphocyte count × 10 ⁹ /L	1.0 (0.6–1.4)	1.0 (0.7–1.5)	0.9 (0.6–1.3)	0.280
Neutrophil count × 10 ⁹ /L	3.9 (2.8–5.6)	3.3 (2.7–5.0)	4.1 (2.8–6.1)	0.088
Platelet count × 10 ⁹ /L	201 (139–250)	197 (143–246)	205 (139–265)	0.743
Alanine aminotransferase U/L	28 (17–42)	27 (19–42)	29 (16–43)	0.879
Aspartate aminotransferase U/L	29 (20–47)	29 (20–41)	30 (20–50)	0.549
Creatinine μmol/L	69.0 (57.7–86.8)	73.0 (62.7–89.5)	65.8 (53.7–83.8)	0.023

Note: CCBs, Calcium channel blockers

Characteristic	Total(N = 198)	ACEI/ARB(N = 74)	Non-ACEI/ARB(N = 124)	P
Urea mmol/L	5.0 (4.0-7.2)	5.3 (4.1–7.3)	4.9 (3.9–7.1)	0.376
Antihypertensive drugs - no. (%)				
CCBs	149 (75.3)	35 (47.3)	114 (91.9)	< 0.001
beta-blockers	52 (26.3)	25 (33.8)	27 (21.8)	0.063
Diuretic	15 (7.6)	11 (14.9)	4 (3.2)	0.004
ACEIs	16 (8.1)	16 (21.6)	0	< 0.001
ARBs	58 (29.3)	58 (78.4)	0	< 0.001
Hospital stay, median (IQR) - days	14 (9–21)	13 (9–19)	14 (10–23)	0.218
Follow-up time, median (IQR) - days	38 (29–53)	39 (29–50)	38 (30–54)	0.511
Adverse event - no. (%)				
Severe illness	87 (43.9)	22 (29.7)	65 (52.4)	0.002
ARDS	69 (34.8)	16 (21.6)	53 (42.7)	0.003
Acute liver injury	37 (18.7)	16 (21.6)	21 (16.9)	0.413
Acute kidney injury	37 (18.7)	11 (14.9)	26 (21.0)	0.287
Death - no. (%)	22 (11.1)	6 (8.1)	16 (12.9)	0.299
Note: CCBs, Calcium channel blockers				

Primary outcomes

Using the Kaplan-Meier survival curve and the Cox-regression analyses, we did not find any significant differences in mortality in the ACEI/ARB group and non-ACEI/ARB group ($P = 0.27$; Table 1; Fig. 1A). Similar results found in the ARB group compared non-ARB group and ACEI group compared to the non-ACEI group. The Kaplan-Meier survival curve showed a trend of improved survival among patients treated with ARB when compared with the group not treated with ARB (Fig. 1B). A similar trend was observed by the multivariate regression analysis (adjusted hazard ratio, 0.27; 95% CI, 0.07–1.02; $P = 0.054$; Table 3). Using the Kaplan-Meier survival curve and the Cox-regression analyses, we did not find any significant differences in mortality in the ACEI group and the non-ACEI group (Fig. 1B; Table 3). The Kaplan-Meier survival curve and the Cox-regression analyses showed a better survival in the ARB groups than the ACEI group (adjusted hazard ratio, 0.03; 95% CI, 0.00-0.58; $P = 0.02$; Fig. 1C; Tables 2 and 3), although there

was no significant difference of the mortality rate between ACEI and ARB groups ($P=0.059$; Tables 2 and 3).

Table 2
Characteristics of Patients with COVID-19 of treatment with ACEI compared to ARB

Characteristic	ARB (N = 58)	ACEI (N = 16)	P
Age, median (IQR) - yr	65 (56–73)	67 (54–73)	0.916
Female sex - no. (%)	23 (39.7)	5 (31.2)	0.772
Comorbidities - no. (%)			
Diabetes	17 (29.3)	6 (37.5)	0.531
Cardiovascular disease	18 (31.0)	4 (25.0)	0.764
Cerebrovascular disease	6 (10.3)	3 (18.8)	0.396
Malignancy	5 (8.6)	2 (12.5)	0.640
Chronic kidney disease	2 (3.4)	0	1.000
Chronic obstructive pulmonary diseases	1 (1.7)	0	1.000
Chronic liver disease	1 (1.7)	0	1.000
Fever - no. (%)	49 (84.5)	13 (81.3)	0.715
Respiratory rate, median (IQR)	20 (18–21)	20 (19–22)	0.306
Pulse, median (IQR)	84 (80–90)	88 (77–95)	0.743
Systolic blood pressure	134 (130–145)	135 (121–148)	0.741
Diastolic blood pressure	78 (74–86)	80 (72–90)	0.880
Laboratory data, median (IQR)			
White blood cell count $\times 10^9/L$	5.3 (4.4–6.6)	4.9 (3.9–8.4)	0.790
Lymphocyte count $\times 10^9/L$	1.1 (0.7–1.5)	0.9 (0.5–1.3)	0.208
Neutrophil count $\times 10^9/L$	3.3 (2.8–4.8)	2.9 (2.4–6.0)	0.764
Platelet count $\times 10^9/L$	210 (137–250)	186 (149–214)	0.337
Alanine aminotransferase U/L	27 (19–42)	27 (18–33)	0.729
Aspartate aminotransferase U/L	30 (23–41)	24 (18–39)	0.249
Creatinine $\mu\text{mol/L}$	71.4 (60.2–89.3)	78.8 (67.8–107.0)	0.274
Urea mmol/L	5.1 (4.0–6.4)	6.5 (4.8–10.6)	0.054
Antihypertensive drugs - no. (%)			

Note: CCBs, Calcium channel blockers

Characteristic	ARB (N = 58)	ACEI (N = 16)	P
CCBs	27 (46.6)	8 (50.0)	0.807
beta-blockers	19 (32.8)	6 (37.5)	0.723
Diuretic	10 (17.2)	1 (6.3)	0.437
ACEIs	0	16 (100.0)	< 0.001
ARBs	58 (100.0)	0	< 0.001
Hospital stay, median (IQR) - days	14 (10–19)	11 (7–16)	0.130
Follow-up time, median (IQR) - days	46 (29–54)	23 (13–38)	0.003
Adverse event - no. (%)			
Severe illness	15 (25.9)	7 (43.8)	0.166
ARDS	9 (15.5)	7 (43.8)	0.015
Acute liver injury	11 (19.0)	5 (31.3)	0.291
Acute kidney injury	7 (12.1)	4 (25.0)	0.238
Death - no. (%)	3 (5.2)	3 (18.8)	0.111
Note: CCBs, Calcium channel blockers			

Table 3
Risks of severe illness, ARDS and death by treatment with ARBs or ACE inhibitors

		Unadjusted	Adjusted ¹	Adjusted ²
ACEI/ARB vs. non-ACEI/ARB	Severe illness	0.38 (0.21–0.71)	0.34 (0.18–0.66)	0.29 (0.14–0.60)
	ARDS	0.37 (0.19–0.71)	0.31 (0.15–0.63)	0.27 (0.13–0.58)
	Death	0.64 (0.25–1.63)	0.63 (0.24–1.63)	0.55 (0.20–1.57)
ARB vs. non-ARB	Severe illness	0.33 (0.17–0.65)	0.29 (0.14–0.59)	0.25 (0.11–0.54)
	ARDS	0.24 (0.11–0.54)	0.20 (0.09–0.46)	0.18 (0.07–0.43)
	Death	0.35 (0.10–1.20)	0.33 (0.10–1.12)	0.27 (0.07–1.02)
ACEI vs. non-ACEI	Severe illness	0.99 (0.35–2.78)	1.06 (0.36–3.11)	1.01 (0.32–3.16)
	ARDS	1.51 (0.53–4.23)	1.52 (0.53–4.41)	1.52 (0.50–4.61)
	Death	2.39 (0.70–8.11)	3.04 (0.87–10.60)	2.81 (0.76–10.30)
ARB vs. ACEI	Severe illness	0.45 (0.14–1.42)	0.42 (0.13–1.37)	0.38 (0.10–1.53)
	ARDS	0.24 (0.07–0.80)	0.22 (0.06–0.78)	0.21 (0.05–0.83)
	Death	0.21 (0.04–1.06)	0.06 (0.01–0.53)	0.03 (0.00–0.58)
The risks of Critical illness and ARDS were assessed by logistic regression; the Cox-regression model evaluated the risk of death.				
¹ Adjusted for age and sex. ² Adjusted for age, sex, and all the comorbidities of COVID-19 listed in Table 1.				

Secondary outcomes

The severe disease incidence was lower in ACEI/ARB treated group than in non-ACEI/ARB group (29.7% versus 52.4%; $P = 0.002$; Fig. 1D) with an odds ratio (OR) of 0.29 (95% confidence interval [CI], 0.14–0.60) after adjusting for other potential risk factors ($P = 0.001$). Also, the incidence of severe illness was lower in the ARBs treated group vs. the group not treated with ARBs [25.9% (15 of 58) vs. 51.4% (72 of 140), respectively; $P = 0.001$; Fig. 1D], which remained significant after adjusting for confounders. The

occurrence rate of severe illness did not change based on the use of ACEI. Compared with ACEI and ARBs, there was no significant difference in the occurrence rates of severe illness ($P = 0.172$).

The occurrence of ARDS was lower in ACEI/ARB group than in non-ACEI/ARB group (21.6% versus 42.7%, $P = 0.003$; Fig. 1D) with OR (95%CI) of 0.27 (0.13–0.58) after adjusting confounders ($P = 0.001$). The ARB treated patients group had a significantly lower rate of ARDS than the group not treated with ARB (15.5% versus 42.9%, $P < 0.001$; Fig. 1D), with OR (95%CI) of 0.18 (0.07–0.43) after adjusting for potential risk factors. There was no significant difference in the occurrence of ARDS between those who treated with or without ACEI. In a comparison between ACEI and ARB, the incidence of ARDS was lower in ARB than in the ACEI group (15.5% versus 43.8%, $P = 0.020$; Fig. 1D), with OR (95%CI) of 0.21 (0.05–0.83) after adjusting confounders ($P = 0.026$).

There were no significant differences between ACEI/ARB or ARB treated and the group not treated in other major adverse events (Tables 1 and 2).

Discussion

We investigated the differential effects of using ACEI and ARB among COVID-19 patients. The results showed a strong association between ARB treatment and reduced rate of severe illness and ARDS. These findings potentially indicate a protective role for the use of ARB in COVID-19. These observations were not replicated when the use of ACEI was the independent variable.

In our study, more than one-third of patients were on treatment with ACEI/ARB. Not surprisingly, ARB was used in the majority (78.4%), as Chinese patients' compliance decreases with ACEI is used¹³ primarily due to the higher incidence of ACEI-induced cough in Asian population⁷. While we showed a potential benefit from the use of ACEI/ARB on the rate of severe illness and ARDS, the advantage was solely limited to the use of ARB among COVID-19 patients.

Recently, Zhang et al. reported that ACEI/ARB utilization could be associated with reduced mortality of COVID-19 patients who had a history of hypertension⁵. As the majority of patients in Zhang et al. study predominantly received ARB, the observed survival benefit could be due to ARB rather than ACEI⁵. Li et al. found the use of ACEI/ARB not to be associated with illness severity or mortality¹⁴, suggesting the uncertainties related to the effects of the use of ACEI and ARB on the outcome of COVID-19 patients.

SARS-CoV-2 uses the ACE2 receptor for entry into target cells¹⁵. ACE2 is predominantly expressed by epithelial cells of the lung, intestine, kidney, heart, and blood vessels¹⁶. Animal studies have shown that expression of ACE2 is increased by ACEI/ARB¹⁷. Thus, they may facilitate infection with COVID-19. Treating COVID-19 patients with ACEI and ARB leads to increased ACE2 receptors in the lung. However, enhanced ACE2 activity as a result of the treatment with RAAS inhibitors showed an essential effect in response to acute injury in animal models¹⁸. In preclinical models of other viral infections, the restoration of ACE2 by the administration of recombinant ACE2 appeared to reverse devastating lung-injury

processes¹⁹. In experimental animal models, the effects of ACEI and ARB on the ACE2 levels have been reported variably^{6,20,21}. Our study indicated a different effect of the use of ACEI or ARBs to COVID-19 patients but we couldn't know the ACE2 true levels in patients induced by ACEI or ARBs.

Acute respiratory distress syndrome (ARDS) is a leading cause of death in COVID-19 patients². In the present study, we showed that treatment with ARB, but not ACEI, was associated with reduced risk of severe illness and ARDS. The frequency of that while was not statistically different, however, there was an impressive trend towards ARB benefits. A previous study showed that the use of ACEI and ARBs was associated with considerable discrepancies in ACE2 expression in animal experiments⁶. Wang et al. recently showed that the use of ARB was associated with an increased ACE2 protein by approximately 2-fold folds in the heart of aorta-constricted mice²². Furthermore, Lely et al. found no effect of ACEI treatment on ACE2 protein expression in renal biopsy samples of patients²³. Contrary to Li et al study¹⁴, our results showed that the use of ACEI/ARB was associated with the severity or mortality of COVID-19 patients with a history of hypertension. Further analysis indicated that the use of ACEI vs. ARB was associated with a significantly different incidence of ARDS and mortality (Figs. 1A and 1D).

Our findings warrant confirmation in prospective studies with engagement of larger sample sizes and multiethnic populations. As ACE2 polymorphism is correlated with the extent of ACE2 expression, patients from different races and ethnicities may show the variable protective effect of these medications among patients with COVID-19 and history of hypertension^{24,25}. This hypothesis, itself, warrants further investigations. Also, future mechanistic studies in humans are required to understand the unique interplay between SARS-CoV-2 infection and the RAAS network leading to modifications in ACE2 levels.

Conclusions

The use of ARB, but not ACEI, was associated with a reduced rate of severe illness and ARDS, indicating their potential protective impact in COVID-19. Further large sample sizes and multiethnic populations are warranted to confirm our findings.

Declarations

Acknowledgements:

This work was supported by the National Natural Science Foundation (grants 81772046 and 81971816 to Dr. Peng) and the Special Project for Significant New Drug Research and Development in the Major National Science and Technology Projects of China (2020ZX09201007 to Dr. Peng).

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information ✉

Affiliations

Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China.

Lianjiu Su, Jiahao Zhang, Nanhui Jiang, Li He, Qin Xie, Rong Huang, Fang Liu, Ying Feng, Zhongyi Sun, Zhiyong Peng.

Department of Respiratory and Critical Care Medicine, Wuhan Fourth Hospital; Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.

Jie Yang, Qiaofa Lu.

Division of Nephrology in Hypertension, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA

Kianoush B. Kashani.

Contributions

Drs Z. Peng, Z. Sun and Q. Lu designed the study. L Su, J Zhang, N Jiang, J Li, J Yang, L He, Q Xie, R Huang, F Liu, F Yuan, Y Feng, J Jiang, and R. Liu analyzed the data and performed the statistical analyses. L. Su, Z. Sun, J Yang, and J Li drafted the initial manuscript. B. Kashani made a critical revision of the initial manuscript. All authors reviewed the drafted manuscript for critical content and approved the final version.

Ethics declarations

Conflict of interest

Lianjiu Su declares that he has no conflict of interest. Jiahao Zhang declares that he has no conflict of interest. Nanhui Jiang declares that he has no conflict of interest. Jie Yang declares that he has no conflict of interest. Li He Zhang declares that he has no conflict of interest. Qin Xie declares that he has no conflict of interest. Rong Huang declares that he has no conflict of interest. Ying Feng declares that he has no conflict of interest. Kianoush B. Kashani declares that he has no conflict of interest. Qiaofa Lu

declares that he has no conflict of interest. Zhongyi Sun declares that he has no conflict of interest. Zhiyong Peng declares that he has no conflict of interest.

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patient.

References

1. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020.
2. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020.
3. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science*. 2020;367(6485):1444–8.
4. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. *N Engl J Med*. 2020;382(17):1653–9.
5. Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. *Circ Res*. 2020.
6. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation*. 2005;111(20):2605–10.
7. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. *Drug Saf*. 1999;21(1):23–33.
8. World Health Organization. Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans 2020.
9. Ferguson ND, Fan E, Camporota L, et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. *Intensive Care Med*. 2012;38(10):1573–82.
10. Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). *Mil Med Res*. 2020;7(1):4.

11. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract.* 2012;120(4):c179–184.
12. European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guideline Panel C, Panel m, representative EGB. EASL Clinical Practice Guidelines: Drug-induced liver injury. *J Hepatol.* 2019;70(6):1222–61.
13. Burnier M, Brunner HR. Angiotensin II receptor antagonists. *Lancet.* 2000;355(9204):637–45.
14. Li J, Wang X, Chen J, et al. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. *JAMA Cardiol. Published online April 23, 2020. doi:10.1001/jamacardio.2020.1624.*
15. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell.* 2020;181(2):281–92 e286.
16. Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. *J Med Virol.* 2020.
17. Sriram K, Insel PA. Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence. *Clin Pharmacol Ther.* 2020.
18. Kassiri Z, Zhong J, Guo D, et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. *Circ Heart Fail.* 2009;2(5):446–55.
19. Gu H, Xie Z, Li T, et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. *Sci Rep.* 2016;6:19840.
20. Hamming I, van Goor H, Turner AJ, et al. Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats. *Exp Physiol.* 2008;93(5):631–8.
21. Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. *Am J Physiol Renal Physiol.* 2009;296(2):F398–405.
22. Wang X, Ye Y, Gong H, et al. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1–7)-Mas axes in pressure overload-induced cardiac remodeling in male mice. *J Mol Cell Cardiol.* 2016;97:180–90.
23. Lely AT, Hamming I, van Goor H, Navis GJ. Renal ACE2 expression in human kidney disease. *J Pathol.* 2004;204(5):587–93.
24. Lu N, Yang Y, Wang Y, et al. ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects. *Mol Biol Rep.* 2012;39(6):6581–9.
25. Cao Y, Li L, Feng Z, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. *Cell Discov.* 2020;6:11.

Figures

Figure 1

Effects of ARBs and ACE inhibitors on the severe illness, ARDS and survival in Covid-19 patients. (A)Kaplan-Meier survival curves of the effects of treatment with ACEI/ARB on overall survival in patients with Covid-19. (B) Kaplan-Meier survival curves of the effects of treatment with ACEI or ARB alone on overall survival in patients with Covid-19. (C) Kaplan-Meier survival curves of the effects of treatment with ACEI compared to ARB on overall survival in patients with Covid-19. (D)The incidence rates of severe illness and ARDS by treatment with ACEI/ARB, ACEI alone, and ARB alone.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [OnlineGraphicalAbstract.Png](#)